Group 1 - The company maintains profit forecasts of 2.5 billion and 3.2 billion for 2025 and 2026, respectively, with current stock price corresponding to 21x and 17x P/E for those years, indicating a 50% upside potential [1] - The company is viewed positively as a leader in collagen protein restructuring, with recommendations to strategically position for the upcoming Double Eleven shopping season [1] - Short-term impacts from events are gradually dissipating, with self-broadcasting continuing to show strong growth and brand acquisition efforts recovering [2][3] Group 2 - The company has successfully optimized its self-broadcasting matrix and product selection strategy, maintaining good growth despite short-term event impacts, with GMV growth exceeding 50% for the 可复美 brand in July and August [3] - The company has established multiple product lines under the 可复美 brand, including collagen repair series and focus series, with strong performance in the collagen repair series [4] - As the Double Eleven shopping season approaches, increased broadcasting frequency is expected to drive brand momentum and recovery in customer acquisition [5]

Group 1 - The company maintains profit forecasts of 2.5 billion and 3.2 billion for 2025 and 2026, respectively, with current stock price corresponding to 21x and 17x P/E for those years, indicating a 50% upside potential [1] - The company is viewed positively as a leader in collagen reconstruction, with a recommendation to strategically position for the upcoming Double Eleven shopping season [1][5] - Short-term impacts from events are gradually dissipating, with self-broadcasting continuing to show strong growth and brand revitalization efforts progressing [2][3] Group 2 - The company has successfully optimized its self-broadcasting matrix and product selection strategy, achieving over 50% GMV growth for the 可复美 brand in July and August [3] - The product innovation and nurturing processes are progressing smoothly, with a strong foundation in R&D and marketing, leading to a rich product matrix that supports long-term growth [4] - As the Double Eleven season approaches, the recovery of broadcasting is expected to drive brand momentum back on track, with positive developments in medical device certifications contributing to incremental growth [5]

Core Viewpoint - The article discusses the recent developments in the domestic beauty market, highlighting the completion of a Series B funding round for HuazhiXiao, led by domestic beauty giant Proya, and the strategic shifts among the top ten domestic beauty companies as they seek new growth avenues amid a slowing market [3][4]. Group 1: Financial Performance of Top Domestic Beauty Companies - Proya, Shangmei, and Shanghai Jahwa ranked as the top three domestic beauty companies, with Proya achieving a revenue of 5.362 billion yuan in the first half of the year, surpassing half of last year's total revenue [5][6]. - Shangmei's revenue grew by 17.3% year-on-year to 4.108 billion yuan, with net profit increasing by 34.7% [5][6]. - The top ten domestic beauty companies saw eight achieve revenue growth, and seven companies reported positive net profit growth, indicating a robust overall performance [6][8]. Group 2: Strategic Shifts and Market Positioning - The top domestic beauty companies are rapidly building multi-brand matrices and advancing overseas strategies to adapt to the slowing domestic market [3][4]. - Proya's skincare segment remains dominant, while its hair care and color cosmetics categories have shown significant growth, with hair care growing by 131.25% and color cosmetics by 25.79% [11]. - Shangmei's main brand, Han Shu, generated 3.344 billion yuan in revenue, while its new brand, newpage, focusing on children's skincare, achieved a remarkable 146.5% growth [14][16]. Group 3: International Expansion and Investment Strategies - Proya aims to enter the top ten global cosmetics companies by 2035, targeting a revenue of at least 50 billion yuan, and is actively pursuing international market opportunities [22][23]. - The investment in HuazhiXiao is a strategic move for Proya to enhance its multi-brand strategy and recognize HuazhiXiao's global potential [23]. - Water Sheep Co. is also focusing on international expansion, with a goal to become a global luxury beauty brand management group, launching a "10+3" global strategy [26][28]. Group 4: Challenges and Future Outlook - The domestic beauty market is facing challenges such as slowing growth and increased competition, prompting companies to seek international opportunities to escape price wars [29]. - Companies that possess product originality, brand narrative capabilities, and cross-market operational efficiency are more likely to transition from "Chinese leaders" to "global players" [29].

Summary of Giant Biogene Holding Co Ltd (2367.HK) Conference Call Company Overview - **Company**: Giant Biogene Holding Co Ltd (2367.HK) - **Industry**: Consumer (Biotech and Skincare) - **Market Cap**: US$6,931.1 million - **Current Stock Price**: HK$53.95 - **Price Target**: HK$78.00, representing a 45% upside from the current price [7][21] Key Financial Highlights - **1H Results**: - Sales increased by 23% - Net Profit (NP) rose by 20% - Operating Profit (OP) was approximately 5% above market expectations [2][3] - **Sales Growth Forecast**: - 2025: 25% increase - 2026: 27% increase - 2027: 27% increase [12][15] - **Net Profit Growth Forecast**: - 2025: 18% - 2026: 24% - 2027: 27% [15] Marketing and Sales Strategy - **Marketing Efficiency**: Improvement noted in 1H results, with a decline in Advertising & Promotion (A&P) expenses for the first time on a semiannual basis [4] - **Sales Channels**: - Online sales grew by 25% - Offline sales increased by 18% - JD Health saw a significant growth of 134% [3] - **KOL Livestreaming Impact**: Temporary disruption due to unfavorable publicity, but recovery is expected [4] Strategic Direction - **In-house Livestreaming**: Shift towards strengthening in-house livestreaming and diversifying influencer partnerships [4] - **Product Innovation**: Emphasis on R&D and product innovation as a competitive advantage [5] Valuation and Price Target Changes - **Price Target Increase**: From HK$74 to HK$78 based on higher EPS estimates [16] - **Valuation Metrics**: - Target P/E remains at 30x for 2025 estimates - Bull-case scenario suggests a target of HK$91.00 with a P/E of 33x [21][29] - Bear-case scenario suggests a target of HK$45.00 with a P/E of 19x [17][31] Risks and Opportunities - **Opportunities**: - Potential growth in aesthetics products not yet priced in - Expected strong sales growth driven by core brands and new product approvals [25][35] - **Risks**: - Competition in the industry may impact margins - Delays in the approval of new aesthetic products could hinder growth [36] Conclusion - **Investment Thesis**: The company is positioned well within the biotech market with a strong growth outlook, driven by innovative products and effective marketing strategies. The current stock price presents an attractive entry point for long-term investors, with significant upside potential as the market begins to recognize the value of its aesthetic product offerings [25][21]

Core Viewpoint - The performance of leading medical beauty companies is diverging amid industry adjustments, with Giant Biological leading in revenue growth while Huaxi Biological and Fulejia face significant declines in performance [2][5][10]. Group 1: Company Performance - Giant Biological reported a revenue of 31.13 billion yuan with a year-on-year growth of 22.5% and a net profit of 11.82 billion yuan, reflecting a 20.2% increase [5][11]. - Huaxi Biological's revenue fell to 22.61 billion yuan, a decrease of 19.57%, with net profit dropping by 35.38% to 2.21 billion yuan [3][4]. - Fulejia's revenue decreased to 8.63 billion yuan, down 8.15%, and net profit fell by 32.54% to 2.3 billion yuan [4][9]. Group 2: Strategic Adjustments - Huaxi Biological attributed its revenue decline to a drop in income from its skin science innovation transformation business, which saw a 33.97% decrease to 9.12 billion yuan [5][7]. - Fulejia's revenue drop was linked to the optimization of offline channels, which impacted sales, while its marketing expenses increased by 39.56% to 4.2 billion yuan [6][10]. - Both companies are undergoing strategic transformations to address their performance issues, with Huaxi Biological implementing significant reforms and Fulejia focusing on improving channel quality [8][10]. Group 3: Industry Trends - The medical beauty industry is shifting from a focus on "traffic dividends" to "technical barriers," with the competition intensifying between hyaluronic acid and recombinant collagen products [2][13]. - The market for recombinant collagen products is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [14]. - Companies are increasingly recognizing the importance of research and development capabilities, patent strategies, and compliance as key competitive factors in the evolving landscape of the medical beauty industry [16].

Core Viewpoint - The development paths of medical beauty companies are diverging amid industry adjustments, with three leading companies—Hua Xi Bio, Juzi Bio, and Fulejia—reporting significantly different half-year results, reflecting a shift from "traffic dividends" to "technical barriers" in the industry [1] Group 1: Company Performance - Juzi Bio led with a revenue of 31.13 billion yuan and a year-on-year growth rate of 22.5% [4] - Hua Xi Bio reported a revenue of 22.61 billion yuan, a decline of 19.57% year-on-year, marking its worst interim report since listing [2][3] - Fulejia's revenue was 8.63 billion yuan, down 8.15% year-on-year, with a net profit drop of 32.54% [3][4] Group 2: Strategic Adjustments - Hua Xi Bio attributed its revenue decline to a drop in income from its skin science innovation transformation business, which saw a 33.97% decrease to 9.12 billion yuan [5][6] - Fulejia's revenue drop was linked to offline channel optimization, which increased sales expenses by 39.56% to 4.2 billion yuan [5][9] - Juzi Bio's growth was driven by the sales increase of professional skin care products, contributing 99.7% of its revenue [10][11] Group 3: Market Dynamics - The medical beauty industry is experiencing a shift, with the competition now focusing on research and development capabilities, patent layouts, and compliance [17] - The market for recombinant collagen products is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [15] - Hua Xi Bio is expanding into recombinant collagen while maintaining its position in hyaluronic acid, indicating a dual strategy to adapt to market changes [15][16]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 ...

Summary of Conference Call on Recombinant Collagen Industry Industry Overview - Recombinant collagen technology has gained popularity in the beauty and skincare industry due to its ability to reduce allergic reactions associated with animal-derived collagen and optimize production costs [1][2] - The industry has seen significant supply-side innovations since 2022, with advancements in gene engineering technology facilitating the commercial production of recombinant collagen [2] Key Companies Jinbo Biotechnology - Jinbo Biotechnology is a leading player in the recombinant collagen medical aesthetics sector, with revenue projected to grow from 160 million yuan in 2020 to 1.44 billion yuan in 2024, achieving a compound annual growth rate (CAGR) of over 70% [1][5] - The company's profit is expected to reach 730 million yuan in 2024, with a CAGR exceeding 100% [5] - Jinbo's new low-temperature gel filler product, approved in 2025, is anticipated to capture market share from animal-derived and regenerative materials [6] - The company plans to implement precise marketing strategies and product innovations to promote new products in the second half of the year [6] Juzhi Biotechnology - Juzhi Biotechnology has made significant strides in the functional skincare sector with products like the "collagen stick" and is expanding into niche markets such as scalp and intimate care [1][7] - The company benefits from national policy support, which has solidified its leading position in the industry [7] - Juzhi has transitioned to direct-to-consumer (DTC) online channels, enhancing sales performance through partnerships with top influencers on platforms like Tmall and Douyin [3][13] Jingbo Biotechnology - Jingbo has achieved progress in the research and certification of recombinant collagen products, accelerating its international market expansion [1][8] - The company has received certifications for functional skincare products in the U.S., Saudi Arabia, and Thailand, contributing to significant revenue growth [8] - Profit forecasts for Jingbo indicate 1.05 billion yuan in 2025 and 1.4 billion yuan in 2026, with a valuation of approximately 30 times earnings in 2025, decreasing to below 25 times in 2026 [9][10] Market Trends and Future Outlook - The acceptance of new products and materials by consumers is increasing, leading to the emergence of industry leaders like Jinbo and Juzhi in the medical aesthetics and functional skincare sectors [4] - The market for recombinant collagen is expected to grow as companies continue to innovate and expand their product offerings [6][7] - The focus on online sales channels and influencer marketing is driving growth in the skincare sector, with Juzhi's online sales showing exceptional performance [3][13] Important Considerations - Future performance indicators to watch include sales growth during the September and October periods, particularly around the Double Eleven shopping festival [16] - The approval of new medical aesthetic products will serve as a significant catalyst for growth, as current valuations primarily reflect cosmetics business performance [16][17] - Jinbo and Juzhi's advancements in recombinant collagen technology position them well for sustained growth in the evolving beauty and skincare market [18]

Summary of Giant Biogene Holding (2367.HK) Conference Call Company Overview - **Company**: Giant Biogene Holding (2367.HK) - **Industry**: Cosmetics and Skincare Key Points and Arguments Consumer Sentiment and Growth Outlook - Resilient consumer sentiment observed with 35-40% repeat purchases and 60% new consumer mix, indicating strong brand loyalty and market presence [1][3] - Management expressed confidence in achieving FY25 guidance, projecting sales growth of 25-28% year-over-year, targeting revenue between RMB6.9 billion and RMB7.1 billion [8][15] - Online growth expected to accelerate to approximately 30% year-over-year in the second half of FY25, with Double 11 sales anticipated to exceed this pace [3][14] Product Performance and New Launches - Luminous Facial Cream and Tier-2 product lines expected to outperform previous management expectations, while single-use essence may experience slower growth due to prior product content issues [3][9] - New SKUs under the Jiaodian series are set to launch in 1H26, targeting core consumer pain points in a fast-growing category [7][9] - Smaller brands like Keyu and SKIGIN projected to deliver strong performance, with Keyu generating over RMB100 million in sales last year [10][12] KOL (Key Opinion Leader) Strategy - Management noted a strong recovery in KOL promotions, with top KOLs like Austin Li and Sun Jian resuming product endorsements, which is expected to enhance brand visibility and sales [1][6][14] - KOLs have not reported negative feedback regarding product quality, indicating strong consumer trust [3][14] Offline Expansion and Channel Strategy - The company plans to increase its offline presence from 24 stores to over 30 by the end of 2025, with a focus on expanding sales through Sephora [7][12] - Positive feedback received for the Precise and Intensive Repair series, which is expected to contribute to incremental sales growth [12] Risk Factors and Market Position - Key risks include slower-than-expected growth, intensified competition in the skincare market, and potential regulatory challenges [13] - The company maintains a strong brand equity rooted in scientific innovation and a long-term commitment to functional skincare [2][13] Financial Metrics and Valuation - Target price set at HK$71, representing a potential upside of 31.8% from the current price of HK$53.85 [15] - Projected financials include revenue growth to RMB8.78 billion by FY26 and EBITDA growth to RMB3.33 billion by FY26 [15] Additional Important Insights - Management emphasized a disciplined approach to discounting during Double 11, aiming for stable pricing compared to previous shopping festivals [6][14] - The company is collaborating with Umer, a dermatology learning platform, to enhance medical-level endorsements for its products [14] This summary encapsulates the key takeaways from the conference call, highlighting the company's growth strategies, product performance, and market positioning within the cosmetics and skincare industry.

Core Viewpoint - The company demonstrated strong brand resilience and internal management capabilities, achieving significant growth in mid-term performance despite challenges faced in the second quarter [1][2]. Financial Performance - In the first half of the year, the company's revenue and net profit attributable to shareholders increased by 22.5% and 20.2% year-on-year, respectively [1]. - The gross margin and net profit margin remained high at approximately 82% and 38% [1]. Revenue Drivers - The main revenue growth drivers were online direct sales through e-commerce platforms (such as JD.com) and offline direct sales, which accounted for 75% of total revenue [1]. - Online direct sales to e-commerce platforms increased by 134%, while offline direct sales grew by 74% year-on-year [1]. Cost Management - The company effectively controlled sales expenses, with the sales expense ratio decreasing by 0.86 percentage points year-on-year, allowing for sufficient marketing investment in the second half of the year [2]. - The good control of sales expenses is attributed to the balanced development across various channels and the reduction in promotional activities due to the product issues in the second quarter [2]. Future Outlook - The company is expected to see a ramp-up in revenue in the second half of the year, driven by the recovery from short-term impacts, increased investment, and the launch of new products [2]. - Long-term focus on scientific research and commercialization in the collagen sector is recommended, with particular attention to upcoming sales during the Double Eleven shopping festival and the progress of medical device certifications [2]. Earnings Forecast - The earnings forecast for 2025-2027 has been slightly adjusted, with expected earnings per share of 2.33, 2.85, and 3.50 RMB, respectively [2]. - A target price of 81.46 HKD has been set for 2025, based on a 32x PE valuation [2].